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Abstract
Heme oxygenase (HO) degrades heme in concert with NADPH cytochrome P450 reductase (CPR) which donates electrons to
the reaction. Earlier studies reveal the importance of the hydrophobic carboxy-terminus of HO-1 for anchorage to the
endoplasmic reticulum (ER) which facilitates the interaction with CPR. In addition, HO-1 has been shown to undergo
regulated intramembrane proteolysis of the carboxy-terminus during hypoxia and subsequent translocation to the nucleus.
Translocated nuclear HO-1 was demonstrated to alter binding of transcription factors and to alter gene expression. Little is
known about the homologous membrane anchor of the HO-2 isoform. The current work is the first systematic analysis in
a eukaryotic system that demonstrates the crucial role of the membrane anchor of HO-2 for localization at the endoplasmic
reticulum, oligomerization and interaction with CPR. We show that although the carboxy-terminal deletion mutant of HO-2
is found in the nucleus, translocation of HO-2 to the nucleus does not occur under conditions of hypoxia. Thus, we
demonstrate that proteolytic regulation and nuclear translocation under hypoxic conditions is specific for HO-1. In addition
we show for the first time that CPR prevents this translocation and promotes oligomerization of HO-1. Based on these
findings, CPR may modulate gene expression via the amount of nuclear HO-1. This is of particular relevance as CPR is
a highly polymorphic gene and deficiency syndromes of CPR have been described in humans.
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Introduction
Heme oxygenase (HO) is the only known enzyme degrading
pro-oxidant heme to the antioxidant biliverdin, iron and carbon
monoxide [1]. This reaction requires three mol of oxygen and
seven electrons supplied by NADPH cytochrome P450 reductase
(CPR) [2]. There are two relevant isoforms described in the
literature: The inducible HO-1 (33 kDa) is the predominant
isoform in liver and spleen [3,4]. The constitutive HO-2 (36 kDa)
is mainly found in brain and testis [5]. Both HO-isoforms as well
as the CPR are anchored with a stretch of hydrophobic amino
acids to the outer membrane of the endoplasmic reticulum [6,7].
Early experiments with HO-1 obtained from rat liver have
shown that this membrane anchor can be cleaved from
membranes by a low concentration of trypsin resulting in
a 28 kDa form [8]. It was later observed that expression of full
length HO-1 in E. coli leads to a 32 kDa form in membranes and
a carboxy-terminally deleted 30 kDa form in the soluble fraction
[9]. More recent data indicate that these anchorless carboxy-
terminally deleted soluble HO-1 isoenzymes are formed in vivo
under conditions of hypoxia [10]. Although crucial amino acids
for binding to CPR have been mapped to the central part of
HO-1 [11,12], there is also evidence to suggest that the
hydrophobic tail in HO-1 contributes to increased binding
affinity for CPR [13,14]. Thus, regulated intramembrane
proteolysis of the carboxy-terminus of HO-1 under conditions
of hypoxia will also weaken the functional interaction with CPR
leading to a loss in enzyme activity [10].
HO-1 and HO-2 share a high degree of sequence homology:
45% in total and 59% in the highly conserved region (see
‘‘Alignment S1’’). The carboxy-terminal membrane anchor
shows similarities but is less conserved (,15%). A carboxy-
terminally deleted form of HO-1 has been successfully expressed
in E. coli [15]. Subsequent crystallization has greatly facilitated
the elucidation of the catalytic mechanism [16]. The character-
ization of the heme regulatory motifs in HO-2 has also been
based on carboxy-terminal deletion variants [17]. So far
expression of HOs with subsequent purification has only been
done in E. coli bacteria. For the study of full length HOs that are
anchored to the endoplasmic reticulum with their carboxy-
terminus such a prokaryotic expression system is not ideal. The
current study is the first to address expression and purification of
both HO isoforms and their carboxy-terminal deletion mutants
using a eukaryotic expression system. This includes the study of
their subcellular localization under normoxic and hypoxic
conditions using fluorescent fusion proteins and their interaction
with CPR by fluorescence resonance energy transfer (FRET) and
co-purification.
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Materials
Unless stated otherwise, chemicals were purchased in highest
purity from Sigma-Aldrich (Taufkirchen, Germany). Cell culture
media and transfection reagents were received from Invitrogen
(Darmstadt, Germany) or PAA (Pasching, Austria). All restriction
enzymes were obtained from New England Biolabs (Frankfurt/
Main, Germany). pECFP, pEGFP and pEYFP vectors were from
Clontech (Heidelberg, Germany). The pFastBac
TM1 and pCRH
2.1 TOPOH vectors were from Invitrogen. The oligonucleotides
were from Biomers (Ulm, Germany).
Cloning of HOs, CPR and biliverdin reductase
HOs were cloned from human placenta cDNA (FirstChoiceH
PCR ready human placenta cDNA, Ambion, Austin, USA) using
the following primers: HO-1 sense 59-cccagcaccggccggatggag-39
and HO-1 antisense 59-ttcagtgcccacggtaaggaagc-39; HO-2 sense
59-cagaggagcgagacgagcaag-39and HO-2 antisense 59-aggggtaggc-
cagtggtcagtcg-39. The PCR products were cloned into the pCRH
2.1 TOPOH vector before the corresponding inserts were
transferred in the pFastBac
TM1 vector. The respective baculo-
viruses were constructed accordingly to the BAC-TO-BAC
TM
system (Invitrogen). Human CPR cDNA in pUV I was kindly
provided by Dr. F. Gonzalez (National Cancer Institute, National
Institutes of Health, Rockville, USA). A baculovirus encoding
CPR was a generous gift of Dr. D. Schwarz (Berlin, Germany).
Human biliverdin reductase (hBVR) was cloned as previously
described [18]. For the carboxy-terminally deleted HO-1 and
HO-2 isoforms a stop codon was inserted after amino acids 265
or 288, respectively using the QuickChangeH Lightning Site-
Directed Mutagenesis Kit (Agilent Technologies, Waldbronn,
Germany) with specific primers. The sense primers were
synthesized as follows: 59-cacccgctcccaggcttagcttctccgatgg-39
(HO-1) and 59-ccttccgaacagctatgtgagtgctgaggaagcccag-39 (HO-
2). For purification assays a Strep-tag II (IBA BioTAGnology,
Go ¨ttingen, Germany) was fused to the amino-terminus of all
HO-variants in pFastBac
TM1 (S-HOs) by molecular cloning.
HOs were fluorescently labeled with CFP (cyan fluorescent
protein), YFP (yellow fluorescent protein) or GFP (green
fluorescent protein) at their amino-terminus (FP-HOs) using the
corresponding vectors pECFP-C1, pEYFP-C1 and pEGFP-C1,
while CPR was labeled with CFP and YFP at its carboxy-
terminus (CPR-FP) using pECFP-N1 and pEYFP-N1.
Cell culture
HEK293 cells were cultivated in Dulbecco’s Modified Eagle
Medium-High Glucose with 10% fetal bovine serum and 1%
penicillin/streptomycin at 37uC with 5% CO2. For microscopy
assays cells were seeded in imaging plates with a special glass
bottom (zell-kontakt, No ¨rten-Hardenberg, Germany). Lipofecta-
mine LTX was used for transfection with cDNA encoding for
fluorescence protein labeled HO and CPR. The incubation time
was at least 48 h.
For the cultivation of Sf9 cells Sf-900 II serum-free medium
with 10% fetal bovine serum and 1% penicillin/streptomycin was
used. Cells were grown in suspension at 27uC with 140 rpm on
a rotating incubator (New Brunswick scientific, Edison, USA).
The cells were harvested after 72 h of infection with respective
recombinant baculoviruses.
Purification and gel filtration of HOs
Cell pellets from 500 ml Sf9 cell suspension (2610
6 cells/ml)
infected with recombinant baculoviruses were resuspended in
15 ml TEA (triethanolamine)-lysis buffer (50 mM) containing
1 mM EDTA and cOmplete
TM EDTA-free protease inhibitor
cocktail tablets (Roche, Mannheim, Germany). After sonication
the homogenate was incubated with avidin (2 nM, IBA BioTAG-
nology) for 30 min at 4uC. To obtain the cytosolic fraction the
samples were centrifuged at 15,000 g for 2 h at 4uC and filtered
with a 0.4 mm sterile filter (Sarstedt, Nu ¨mbrecht, Germany). A
chromatography system from GE Healthcare Life Sciences
(A ¨KTA
TMpurifier, Freiburg, Germany) was used with a Strep-
TactinH SuperflowH high capacity column (2-ml volume, IBA
BioTAGnology). The following buffers were used: Washing Buffer:
100 mM Tris, 500 mM NaCl, 1 mM EDTA, 1 mM benzami-
dine-HCl, pH 8.0; Elution Buffer: 100 mM Tris, 500 mM NaCl,
1 mM EDTA, 1 mM benzamidine-HCl, 2.5 mM D-desthiobiotin,
pH 8.0 and Regeneration Buffer: 100 mM Tris, 150 mM NaCl,
1 mM EDTA, 1 mM HABA, pH 8.0. The fractions showing
absorption at 280 nm were collected and concentrated with
AmiconH ultra centrifugal filter devices (10 kDa) (Millipore,
Billerica, USA). The protein concentration was measured with
a nanophotometer (Implen, Munich, Germany) against elution
buffer blank.
For gel filtration 150 mg purified protein were used. Gel
filtration buffer contained 50 mM TEA-HCl and 250 mM NaCl,
pH 8.0. The gel filtration was carried out using the A ¨KTA
TM-
purifier with the gel filtration column Superdex 200 10/300 GL
(GE Healthcare Life Sciences). For calibration the gel filtration
Figure 1. Comparison of enzyme activity of full-length HO isoforms. Measurements were made in the presence (black columns) and absence
(grey columns) of exogenous CPR. (A) HO activity measured in cytosolic fractions from Sf9 cells expressing the indicated HO variants. (B) Same
experiments made in homogenates from Sf9 cells. (C) Enzyme activity assay after purification using the Strep-tag/Streptavidin system. Data are shown
as means 6 SEM (n=3, *p,0.05).
doi:10.1371/journal.pone.0035483.g001
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void volume was determined using Blue Dextran (2000 kDa). For
size determination the standard linear equation was calculated
based on the calibration of the column.
Heme oxygenase activity assay
Harvested Sf9 cells were resuspended in 50 mM TEA-HCl,
pH 7.6, containing cOmplete
TM EDTA-free protease inhibitor
cocktail tablets (Roche). For cell lysis the cell suspension was
Figure 2. Comparison of enzyme activity of the carboxy-terminally deleted HO isoforms. Measurements were made in the presence
(black columns) and absence (grey columns) of exogenous CPR. (A) Activity measured in the cytosolic fractions from Sf9 cells expressing the HO
mutants. (B) Measurement in homogenates from infected Sf9 cells. (C) Enzyme activity assay after purification using the Strep-tag/Streptavidin
system. Data are shown as means 6 SEM (n=3, *p,0.05).
doi:10.1371/journal.pone.0035483.g002
Figure 3. Coomassie staining and immunoblot analysis of co-infections of HO-isoforms and CPR in Sf9 cells. (A) S-HO-1/CPR
coinfection (B) S-HO-2/CPR coinfection (C) S-HO-1DC266/CPR coinfection (D) S-HO-2DC289/CPR coinfection. The respective lanes C show cytosolic
fractions (80 mg protein) of the co-infections and lanes P samples after purification (5 mg). For purification Strep-tagged HO isoforms were used in
combination with untagged CPR. Coomassie staining was used to control the degree of purification. Western blot analysis was performed using
specific antibodies against CPR (upper blot) and the HO-isoforms 1 and 2 (lower blot). Panel E and F show a HO-Western-blot analysis for direct
comparison of full-length and truncated isoforms. The molecular weight of the proteins was specified in kDa.
doi:10.1371/journal.pone.0035483.g003
Heme Oxygenases and Cytochrome P450 Reductase
PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e35483sonicated. The resulting homogenate was either used directly or
a cytosolic fraction was obtained by centrifugation at 21,000 g for
30 min at 4uC. For the activity assay 200 ml of homogenate or
cytosolic fraction was used. Purified enzyme was assayed using
a total protein amount of 25 mg. The HO-assay mixture contained
phosphate buffered saline-magnesia buffer, 1 mM glucose-6-
phosphate, 0.75 units/ml glucose-6-phosphate dehydrogenase,
1 mM NADPH (Applichem, Darmstadt, Germany), 25 mM
freshly dissolved hemin (hemin stock solution dissolved in 2 N
NaOH diluted 1:200 with phosphate buffered saline-magnesia
buffer), recombinantly expressed (exogenous) CPR and human
biliverdin reductase (hBVR), which is necessary for the reduction
of biliverdin to bilirubin. The final volume was 500 ml. The
incubation was carried out at 37uC for 1 h in the dark. The
formed bilirubin was extracted with 350 ml chloroform by mixing
thoroughly for 30 sec and centrifugation at 10,000 rpm for 5 min
at 4uC. This step was repeated before absorbance of the
chloroform phase was measured with a Varian spectrophotometer
(Agilent Technologies) at 464 nm and 530 nm. To calculate the
HO-activity (pmol/h/mg) a molar extinction coefficient of
40 mM/cm was used [19].
SDS-PAGE, immunodetection and Coomassie staining
Laemmli sample buffer was added to 5 mg of purified protein
samples or 80 mg of cytosolic fractions. The proteins were
separated on 10% SDS polyacrylamide electrophoresis gels which
were used for either Western blotting or Coomassie staining. A
prestained marker (Fermentas, St. Leon-Rot, Germany) was used
for size control. For immunodetection the separated gels were
blotted on nitrocellulose membranes. After reversible staining with
Ponceau S the membranes were blocked with 5% non-fat dry milk
in TBST (10 mM Tris, 150 mM NaCl, 0,1% (v/v) TweenH20).
The HO-1 and HO-2 antibodies (Stressgen, Enzo Life Sciences,
Lo ¨rrach, Germany) and the CPR antibody (Abcam, Cambridge,
England) were incubated for 2 h in TBST with 1% non-fat dry
milk, washed three times and then incubated with an anti-rabbit
IgG horse radish peroxidase linked antibody (Cell Signaling,
Darmstadt, Germany). Chemiluminescence was examined using
the lumi-light
plus western blotting substrate (Roche). For Coomas-
sie staining the gels were incubated overnight with Coomassie
Brilliant Blue solution (0.02% Coomassie Brilliant Blue -G250, 5%
aluminium sulfate, 10% ethanol, 2% orthophosphoric acid).
Excess staining solution was removed with washing solution
(10% ethanol, 2% orthophosphoric acid) for more than 1 h [20].
Detection was carried out using a colour scanner.
FRET measurements using the sensitized emission
method
A Varian spectrofluorometer (Agilent Technologies) was used
for FRET studies. Homogenates and cytosolic fractions from Sf9
cells infected with respective baculoviruses (CFP-HO-1; CFP-HO-
1DC266; CFP-HO-2; CFP-HO-2DC289 and CPR-YFP) were
tested at 37uC in a heated cuvette holder. FRET measurements
were based on the sensitized emission method using three
channels. In the donor channel an excitation wavelength of
436 nm and an emission wavelength of 476 nm were selected. For
detection of YFP the acceptor channel with an excitation
wavelength of 515 nm and an emission wavelength of 527 nm
was used. This resulted in a FRET channel with an excitation
wavelength of 436 nm and an emission wavelength of 527 nm.
The excitation- and emission-slits were 5 nm.
The samples were diluted with lysis buffer to similar
fluorescence intensity in the YFP-channel before starting measure-
ments in all three channels. To make up for unspecific
fluorescence of cytosolic components the background was de-
termined with uninfected Sf9 cytosol. The background was
proportional to the protein concentration of the samples and
was substracted from the measured intensities. The calculated
intensities were designated in the following equations as CFP and
YFP. The corrected FRET (FRET
c) considered bleed-through
factors for CFP and YFP and was calculated using the equation:
FRET
c=FRET2(0.4466CFP)2(0.01776YFP) [21]. The bleed-
through factors were determined by the ratio of FRET channel
intensity to corresponding CFP or YFP channel intensities. The
factors corresponded to those described in literature [22]. To
determine the degree of interaction the FRET efficiency (E) was
calculated according to the equation: E=12[CFP/
Figure 4. Specific enzyme activity assay of HO-CPR co-infections after purification. Measurements were made in the presence (black
columns) and absence (grey columns) of exogenous CPR. (A) Co-purifications of full-length Strep-tagged HO-1 and HO-2 (B) Carboxy- terminally
deleted HO isoforms. Data are shown as means 6 SEM (n=3, p,0.05).
doi:10.1371/journal.pone.0035483.g004
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PLoS ONE | www.plosone.org 4 April 2012 | Volume 7 | Issue 4 | e35483Figure 5. Gel filtration analysis of S-HO isoforms after purification. (A) S-HO-1DC266 (B) S-HO-2DC289 (C) S-HO-1 (D) S-HO-2 (E) S-HO-1-CPR
co-purification (F) S-HO-2-CPR co-purification. The elution volume of peak 1 is nearly the void volume of the column and corresponds to sizes
.2000 kDa. Peak 2 corresponds to a size in the range of 40 kDa. Western Blots of the purified samples (P) and the gel filtration-peaks are shown in
the small boxes, detected with the HO-1 antibody (A+C+E) or HO-2 antibody (B+D+F), respectively.
doi:10.1371/journal.pone.0035483.g005
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c6Qd/Qa)] with the quantum yields for the donor
CFP (Qd=0.4) and the acceptor YFP (Qa=0.61) [23,24].
In vivo fluorescence lifetime imaging (FLIM)
HEK293 cells were analyzed at 37uC on the confocal
microscope system A1 from Nikon (Nikon Europe, Kingston,
England) equipped with a Ti-E microscope and an incubation
chamber (Okolab, Naples, Italy) using a 406 oil immersion
objective (NA 1.4, Nikon). Fluorescence lifetimes were measured
in cells expressing only the FRET donor, and in cells expressing
the combination of FRET donor and acceptor. Cells were excited
using a 405 nm pulsed laser. FLIM images of fluorescent cells were
recorded with a four channel time gated detection system (LiMo
module, Nikon) using a CFP bandpass filter (475/20 nm). The
intensities were fitted using a mono-exponential function. The
FRET efficiency (E) was calculated according to the equation:
E=12(tDA/tD), where tDA is the mean fluorescence lifetime of
Figure 6. FRET measurements of HO isoforms and CPR in homogenate (black column) or cytosol (grey column). YFP-GAFA-CFP served
as positive control for FRET-interactions. CPR was tagged with CFP and HO-variants with YFP. Data are shown as means 6 SEM (n=3, p,0.05).
doi:10.1371/journal.pone.0035483.g006
Figure 7. FLIM measurements of CFP-HOs with CPR-YFP in HEK293 cells. Pictures of the HO-CPR co-transfections were made in the CFP
channel (left panels) and YFP channel (middle panels). The right panels show the color coded lifetime of the donor CFP. The corresponding color scale
is shown in the center of the figure. The white bars correspond to 20 mm.
doi:10.1371/journal.pone.0035483.g007
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fluorescence lifetime of cells expressing FRET donor only [24].
Detection of translocation using a confocal laser
scanning microscope
Transfected HEK293 cells were analyzed with the same
microscope used for FLIM. The measurements were made at
37uC with a 606oil immersion objective using the 488 nm laser
for GFP and a 525/50 bandpass filter (emission range of 500–
550 nm). CFP and YFP were excited with 457 nm and 514 nm,
respectively; the corresponding emissions were measured between
464–499 nm and 525–555 nm using the bandpass filters 482/35
and 540/30.
Cells were incubated under hypoxic conditions for 42 h using
an O2/CO2 incubator (Sanyo, Munich, Germany) with 1% O2,
5% CO2 and 94% N2 at 37uC.
Statistical analysis
The results are expressed as means 6 SEM of three
independent experiments. Statistical significance was calculated
using the Student’s t-test with p,0.05.
Results
Differences in CPR dependent HO isoenzyme activity
HO-1 and HO-2 were expressed in Sf9 cells. Measurement of
HO activity in the absence and presence of exogenous CPR in
cytosolic fractions showed a significant difference between both
isoforms: While HO-1 activity was dependent on addition of
exogenous CPR, HO-2 was equally active without addition of
exogenous CPR (Figure 1A). When homogenates of Sf9 cells were
used instead of cytosolic fractions both HO-1 and HO-2 were
catalytically active regardless of exogenous CPR (Figure 1B). This
indicates that endogenous CPR activity in Sf9 cells can support
HO activity, but the functional interaction is lost for HO-1 upon
the preparation of cytosol. After purification both HO isoforms
needed exogenous CPR for full activity (Figure 1C).
We hypothesized that the different ability of HO-1 and HO-2 to
use CPR activity occurring endogenously in Sf9 cell cytosol, may
be due to a loss of the membrane anchor in HO-1 upon
preparation of cytosolic fractions. If this was true carboxy-terminal
deletion mutants of HO-1 and HO-2 should all lose their ability to
use endogenous Sf9 cell CPR activity and behave similarly in
response to exogenous CPR. Figure 2 shows that this is the case
not only in cytosol (Figure 2A), but also in homogenate (Figure 2B)
and after purification (Figure 2C). This supports the idea that the
membrane anchor is crucial for functional interaction with
endogenous CPR activity [13,14] and makes it likely that HO-1
in Sf9 cytosol has lost part of the membrane anchor similar to
what has been described in the literature [9].
Co-purification of HO variants with CPR
In order to compare CPR binding to HO-isoforms with and
without the carboxy-terminal membrane anchor, we tested
whether the interaction between HO and CPR is strong enough
to allow co-purification. A Strep-tag was attached to the amino-
terminus of the HO-variants. After co-infection of Sf9 cells with
recombinant baculoviruses encoding CPR and the respective Strep-
tagged HO variants, the proteins were purified to apparent
homogeneity by affinity chromatography. The Coomassie stained
polyacrylamide gels are shown in Figure 3. In the range of 30 kDa
two bands for the HO-1 protein were apparent for full length HO-
1 (Figure 3A, left panel). Both of these bands were detectable with
an HO-1 antibody directed against several epitopes between
amino acids 1 and 261 (Figure 3A, right panel). For the carboxy-
terminal deletion mutant of HO-1 a similar double band was
apparent (Figure 3C). The upper bands in Figure 3 A and C were
different in molecular weight (Figure 3E) and corresponded to the
respective translation product of HO-1 and HO-1DC266. The
lower bands in Figure 3A and C were identical in size (Figure 3E).
This indicates that the recombinantly expressed carboxy-terminal
deletion variant of HO-1 likely corresponds to the described
carboxy-terminally deleted 30 kDa form [9] while the lower bands
in Figure 3A and C correspond to the 28 kDa cleavage product
described by Yoshida et al. 1991 [8].
For HO-2 a single band was apparent slightly above 34 kDa
and at 34 kDa for the carboxy-terminal deletion mutant of HO-2
(Figure 3B and D, left panel). As expected these bands were
detected by the respective antibody against HO-2 (Figure 3B and
D, right panel). For direct comparison of the molecular weight see
Figure 3F). The protein preparations containing the full-length
isoforms HO-1 and HO-2 showed an additional band at the
height above 72 kDa (Figure 3A and B, left panel). This
corresponds to the size of CPR (78 kDa) and was additionally
identified as CPR by Western blotting (Figure 3A and B, right
panel). In the purified preparations from Sf9 cells co-infected with
recombinant baculoviruses encoding CPR and the respective
carboxy-terminal deletion mutants of HO, CPR was not detect-
able by Coomassie stain (see Figure 3C and D, left panel).
Extremely faint bands were detectable for CPR in the respective
samples by Western blotting (see Figure 3C and D, right panel).
This indicates that although the carboxy-terminal deletion
mutants of HO retain a residual capacity to interact with CPR,
Table 1. FRET efficiencies of HO-CPR co-transfections in
HEK293 cells.





FRET efficiencies (%) with SEM were calculated after measuring the lifetimes of
the samples in HEK 293 cells. CFP-HO-1 single transfection served as donor
control. The mean calculation was carried out after three independent
measurements.
doi:10.1371/journal.pone.0035483.t001
Table 2. Translocation rate of HO isoforms before and after
incubation with hypoxia.





HO-1 1.59 1.59 30.10 3.54
HO-2 0 0 0.43 0.43
HO-1 DC266 100 0 99.04 0.96
HO-2 DC289 100 0 100 0
The rate of cells showing a translocation to the nucleus before (0 h) and after
incubation with hypoxia (42 h) were determined in comparison to total number
of cells. The results consider three independent experiments and are shown as
means (%)6 SEM(%).
doi:10.1371/journal.pone.0035483.t002
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without the HO-membrane anchor.
Enzyme activity of purified HO variants co-expressed
with CPR
The difference in quantitative physical interaction between
purified full length HO co-expressed with CPR versus purified
HO-deletion mutants co-expressed with CPR should also result in
a functional difference in the responsiveness of the enzyme activity
against exogenous CPR. As expected exogenous CPR added to
the purified samples had no significant influence on the catalytic
activity of the full length enzymes (Figure 4A), but significantly
increased enzyme activity for the carboxy-terminal deletion
mutants (Figure 4B). This indicates that the physical interaction
of CPR with the full length enzymes (see Figure 3A and B) also
results in a functional interaction between HO and CPR. Maximal
enzyme activity under optimal conditions was about three times
higher for the carboxy-terminal deletion mutants than for the full
length enzymes (note different axes in Figure 4).
Influence of CPR on HO oligomerization
Gel filtration analysis of purified preparations of the carboxy-
terminally deleted variants of HO-1DC266 (Figure 5A) and HO-
2DC289 (Figure 5B) revealed a single peak around 40 kDa likely
representing monomeric HO. In contrast, analysis of the re-
spective full length enzymes indicates a difference between HO-1
and HO-2: While there was only a small peak around 2000 kDa
representing higher ordered oligomers for HO-1 (Figure 5C, peak
1), the shift from monomers to higher ordered oligomers was
almost complete for full length HO-2 (Figure 5D). Co-expression
of CPR did not influence the amount of monomeric HO-2
(Figure 5F), but substantially reduced the amount of monomeric
HO-1 and increased the peak representing higher ordered HO-1
complexes (Figure 5E). As expected gel filtration analysis of
carboxy-terminally deleted HO-variants did not change in the
absence or presence of CPR (data not shown).
HO-CPR interaction revealed by FRET analysis
As shown in Figure 1A and B, HO-activity of HO-1 but none of
the other HO-forms differs in cytosol versus homogenate. In order
to analyze the physical interaction of HO-variants with CPR in
Sf9 cytosol and homogenate, we compared the respective Sf9 cell
fractions by using FRET measurements. CPR was tagged with
CFP as donor and the HO variants with YFP as acceptor. Our
results indicate that HO-1 but none of the other HO-forms shows
a significantly lower FRET efficiency in cytosol versus homogenate
(Figure 6). This supports the idea that loss of the membrane
anchor of HO-1 upon preparation of cytosol from homogenate
leads to a decreased capacity of HO-1 to interact with CPR. This
is supported by the expected finding that FRET efficiencies were
highest for full length HO-1 and HO-2 and lowest for the
respective carboxy-terminal deletion mutants. The FRET efficien-
cy of HO-1 was in the same range as the positive control YFP-
GAFA-CFP. In this construct previously characterized by our
group both FRET-donor and FRET-acceptor are covalently
linked by a protein [25].
HO-CPR interaction in intact cells revealed by FLIM-FRET
analysis
To measure FRET in intact cells we used FLIM (Figure 7). In
the presence of co-transfected YFP-labeled CPR, full length HO-1
and HO-2 displayed FRET efficiencies of 10% and 7%, while the
carboxy-terminal deletion mutants showed no significant FRET
efficiency over baseline (0–1%) (Table 1). Thus, the membrane
anchors of both HO-1 and HO-2 are important for efficient
interaction with CPR in biochemical fractions as well as in intact
cells.
Translocation of HO-1 but not HO-2 under hypoxia
The carboxy-terminal part of HO-1 is important for subcellular
localization to the endoplasmic reticulum [6,10,26]. Confocal
microscopy of HEK293 cells transfected with amino-terminal
GFP-fusion proteins revealed a granular perinuclear appearance
for full length HO-1 (Figure 8A, left panel) and a homogenous
cytosolic and nuclear fluorescence for GFP-HO-1DC266
(Figure 8B, left panel). An identical granular perinuclear
appearance consistent with a localization to the endoplasmic
reticulum was apparent for the GFP-fusion with full length HO-2
(Figure 8C, left panel). Again the carboxy-terminally deleted form,
GFP-HO-2DC289, showed a homogenous cytosolic and nuclear
fluorescence (Figure 8D, left panel).
Figure 8. Confocal laser scanning analysis of GFP-tagged HO isoforms in HEK293 under hypoxia. The left panels show the cells at time
0 h and the right panels after incubation with 1% oxygen for 42 h. (A) GFP-HO-1; (B) GFP-HO1DC266; (C) GFP-HO-2; (D) GFP-HO-2DC289.
doi:10.1371/journal.pone.0035483.g008
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endoplasmic reticulum to the cytosol and the nucleus. There it can
modulate DNA-binding activity of transcription factors including
AP-1 independently of its catalytic activity [10,27]. We could
confirm the translocation of HO-1 induced by hypoxia (Figure 8A)
and could show that it is specific for HO-1 (Figure 8C): 30.1% of
the cells transfected with HO-1 translocate to the nucleus (Table 2)
and show a more homogenous cytosolic fluorescence after
exposure to hypoxia but only 0.43% of HO-2 transfected cells.
At the same time our results with HO-2DC289 predict that tryptic
cleavage of the membrane anchor of HO-2 would lead to
translocation (Figure 8D) in 100% of the cells in the same range
like HO-1 DC266 (99.04%-Figure 8B).
CPR prevents hypoxic translocation of HO-1
Because it has been shown that oligomerization is crucial for the
stability of HO-1 [26], we hypothesized that the greater stability of
HO-2 in Sf9 biochemical fractions and the greater resistance of
HO-2 for tryptic cleavage of the membrane anchor under
conditions of hypoxia may be due to its more complete
oligomerization (see Figure 5D). Based on this idea, we tested
whether co-expression of CPR which leads to higher ordered HO-
1 complexes (see Figure 5E), may also modulate hypoxic
translocation of HO-1 in intact cells. Figure 9A shows that co-
expression of CPR prevents translocation of HO-1 under
conditions of hypoxia (see red arrows). Figure 9B shows the
analogous control experiment for HO-2.
Discussion
In the present study we show for the first time that CPR
prevents nuclear translocation of HO-1 under hypoxic conditions
and promotes oligomerization of HO-1 into higher ordered
complexes. In addition, we demonstrate that nuclear translocation
of HO under hypoxic conditions occurs in an isoform specific
manner for HO-1. Lastly our study is the first systematic analysis
in a eukaryotic system that demonstrates the crucial role of the
Figure 9. Influence of CPR on the hypoxic translocation of HO in HEK293 cells using confocal microscopy. HEK293 cells were
transfected with YFP-HO-1 (A-row 1) and YFP-HO2 (B-row 1) or co-transfected with YFP-HO1 and CPR-CFP (A-row 2) or YFP-HO2 and CPR-CFP (B-row
2). Cells were analyzed under normoxic conditions using the CFP-channel (column 1) and YFP-channel (column 2) or after hypoxia in the CFP-channel
(column 3) or YFP-channel (column 4). The red arrows in panel A point to typical cells where the translocation of HO-1 (row 1) and its prevention in
the presence of CPR (row 2) are visible. The white bars correspond to 10 mm.
doi:10.1371/journal.pone.0035483.g009
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reticulum, oligomerization and interaction with CPR.
It has been shown by Lin et al. 2007 that hypoxia leads to
translocation of HO-1 to the nucleus which is associated with the
truncation of its carboxy-terminus [10]. Our work on HO-1 in the
current paper confirms these results. Nuclear carboxy-terminally
truncated HO-1 was reported to be catalytically inactive [10]. This
is based on an experiment using an enzyme lacking the last 23
amino acids [10]. At first this is surprising because carboxy-
terminal deletion of 23 amino acids of HO-1 has previously been
shown not to negatively affect HO activity [15] and we fully
confirm this finding in the current study. However, as emphasized
by our current work the catalytic inactivity of the carboxy-
terminally deleted enzyme described in [10] can be explained by
a lack of CPR in the nucleus.
Nuclear HO-1 was demonstrated to alter binding of transcrip-
tion factors involved in oxidative stress independent on degrada-
tion of heme or production of carbon monoxide [10,27]. Our
work shows that CPR not only collaborates with HO-1 in its
enzymatic function, but also influences the amount of nuclear
HO-1 that alters gene expression in the nucleus. This is of
particular relevance as CPR is a highly polymorphic gene [28,29]
and deficiency syndromes of CPR have been described in humans
[30]. Mutations of CPR have recently been shown to differentially
modulate HO-1 activity [31]. Our paper suggests that mutations
in the CPR promoter [32] or CPR deficiency could increase
nuclear HO-1 and lead to subsequent alterations in gene
expression.
Based on FRET experiments, it has recently been demonstrated
that oligomerization is crucial for stability and function of HO-1 in
the endoplasmic reticulum. This oligomerization was shown to be
strongly dependent on the presence of the intact carboxy-terminus
of HO-1 [26]. We fully confirm these findings for HO-1 using
alternate methods in the current paper. In addition, we extend the
findings to HO-2 and show that oligomerization of full length HO-
2 is more complete than oligomerization of full length HO-1 (see
Figure 5B). Only when CPR is co-expressed, HO-1 reaches the
oligomerization level of HO-2 (see Figure 5C). These results
obtained by gel filtration are in line with a recent report that CPR
has an influence on HO-1 oligomerization based on biolumines-
cence resonance energy transfer (BRET) [31]. Because of the
nature of BRET it could only be stated that ‘CPR disrupted or
otherwise influenced the conformation/configuration of the HO-1
multimers’ [31]. Our biochemical results using gel filtration
support this notion and indicate that CPR increases HO-1
oligomerization.
It has been shown that oligomerization is crucial for the stability
of HO-1 [26]. Our observation that co-expression of CPR
increases HO-1 oligomerization and prevents tryptic cleavage of
HO-1 during hypoxia is consistent with this finding. The higher
degree of oligomerization of HO-2 reported in the current study, is
a plausible explanation for the greater stability of HO-2 versus
HO-1. However, it is also conceivable that the carboxy-terminus
of HO-2 is inherently more stable or that it does not contain the
HO-1 specific recognition sequence for a tryptic protease that is
induced by hypoxia. This would also be possible, because the
sequence of the carboxy-termini of HO-1 and HO-2 are not
highly conserved (,15%). It is not ruled out that there exists
a signal in the intact cell that leads to tryptic cleavage of the HO-2
carboxy-terminus and nuclear translocation of HO-2. In fact, the
occurrence of a carboxy-terminally deleted tryptic fragment of
HO-2 has been described after overexpression in E. coli [33].
However, so far our experiments in eukaryotic cells indicate that
HO-2 is quite stable and neither translocates in response to
hypoxia nor in response to different hemin concentrations or
hyperoxia (data not shown).
HO-2 has been suggested to function as an oxygen sensor for
a calcium-sensitive potassium channel in glomus cells of the
carotid and aortic bodies [34,35,36]: HO-2-derived CO maintains
potassium channel activity in normoxia, while hypoxia leads to
a reduction in CO formation, channel closure and depolarisation.
While we demonstrate in the current paper that HO-2 does not
translocate from the endoplasmic reticulum in response to
hypoxia, HO-2 has recently been shown to be reversibly
inactivated under hypoxic conditions by induction of the dithiol
state of the carboxy-terminal heme regulatory motifs (see
‘‘Alignment S1’’) and a subsequent increase of the Kd for heme
well above endogenous heme concentrations [17,37]. Thus, both
HO-isoforms seem to have developed a mechanism of inactivation
under conditions of hypoxia that fits their nature: The inducible
HO-1 is inactivated by irreversible tryptic proteolysis and
translocation away from the endoplasmic reticulum and away
from CPR. The constitutive HO-2 is reversibly inactivated by the
redox state of specific cysteines.
Besides the difference in reversibility there is another crucial
difference between the inactivation mechanism of HO-1 and HO-
2 in response to hypoxia. It has very recently been shown that
there is an interdependence between HO activity and the activity
of cytochrome P450 via competition for binding to CPR [38]. The
translocation of HO-1 under conditions of hypoxia would increase
the amount of CPR that can interact with cytochrome P450 [39],
while the reversible inactivation of HO-2 under hypoxic condi-
tions would not change its binding to CPR. As apparent in
Figure 9, CPR has the capacity to inhibit HO-1 translocation
under hypoxic conditions. This adds another layer of complexity
to the equilibrium between HO-1, CPR and drug metabolizing
cytochrome P450.
In sum, we demonstrate that HO-1 and HO-2 respond
differently to hypoxia in the intact cell, that their oligomerization
status is different and that CPR influences oligomerization and
prevents hypoxic translocation of HO-1 but not of HO-2. From
a pharmacological perspective, it is important to note that hypoxia
may change the competitive binding equilibrium between HO-1,
drug metabolizing cytochrome P450 and their common partner
CPR [38]. Thus hypoxia may not only have a direct inhibitory
effect on heme metabolism but also a possible indirect activating
effect on drug metabolism.
Supporting Information
Alignment S1 Amino acid alignment of human HO-1
and human HO-2. The carboxy-termini marked in yellow are
missing in the HO-1DC266 and HO-2DC289 mutants. Amino
acids marked in green and blue correspond to the CPR binding
sites (11–12). Heme regulatory motifs are marked in red.
Conserved amino acids are marked with ‘‘*’’, while ‘‘:’’ and ‘‘.’’
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